Imaging test to see PD-L1 in solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study tests a new imaging method to see if a special 'tracer' can light up tumors that have a protein called PD-L1, which is a target for immunotherapy. By taking a PET scan, doctors hope to predict whether immunotherapy will work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and in good physical condition (able to do daily activities).
- You have lung cancer, melanoma, or another solid tumor and are about to start immunotherapy treatment.
- You have already had a biopsy that checks for a protein called PD-L1 on your tumor.
- Your doctor expects you to live at least 6 more months.
- Your blood counts and liver and kidney function are within safe levels.
- You have at least one tumor that can be measured on a scan.
- You are not pregnant, can lie still for 30 minutes, and are not claustrophobic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.